Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cardinal Health ( (CAH) ) has shared an announcement.
On August 13, 2025, Cardinal Health entered into an underwriting agreement with major financial institutions for the sale of $1 billion in notes, consisting of $600 million in 4.500% Notes due 2030 and $400 million in 5.150% Notes due 2035. This financial maneuver is part of Cardinal Health’s strategy to optimize its capital structure, potentially impacting its market positioning and offering implications for investors and stakeholders in terms of financial stability and growth prospects.
The most recent analyst rating on (CAH) stock is a Hold with a $110.00 price target. To see the full list of analyst forecasts on Cardinal Health stock, see the CAH Stock Forecast page.
Spark’s Take on CAH Stock
According to Spark, TipRanks’ AI Analyst, CAH is a Neutral.
Cardinal Health’s overall stock score reflects strong revenue growth and strategic acquisitions, which are offset by significant balance sheet challenges and bearish technical indicators. The company’s efforts to mitigate tariff impacts and expand its specialty solutions segment are positive, but financial restructuring is needed to improve stability and liquidity.
To see Spark’s full report on CAH stock, click here.
More about Cardinal Health
Cardinal Health is a healthcare services and products company that primarily focuses on the distribution of pharmaceuticals and medical products to healthcare providers and pharmacies. It operates in the healthcare industry, providing essential services and products to improve the efficiency and effectiveness of healthcare delivery.
Average Trading Volume: 2,173,425
Technical Sentiment Signal: Buy
Current Market Cap: $34.92B
For detailed information about CAH stock, go to TipRanks’ Stock Analysis page.